Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T ...
Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior ...
Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes. A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results